Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR Annual Meeting
02 avr. 2017 13h00 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Executive Changes
20 mars 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing...
Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results
23 févr. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on February 23
09 févr. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...
Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
08 févr. 2017 16h10 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting
08 févr. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis (PVNS)
24 janv. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that the European Commission has granted orphan designation for...
Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
04 janv. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
03 janv. 2017 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Presents Data from FPA144 in Urothelial Cancer at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapies
01 déc. 2016 16h05 HE
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...